Dr. Sattva Neelapu, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Exeter / School Of Postgraduate Medicine And Health Sciences

  Medical School, 1992

• Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy, 2022-04-12

• Idelalisib impacts cell growth through inhibiting translation regulatory mechanisms in mantle cell lymphoma, 2016-06-24

• The Chimeric Antigen Receptor-Intensive Care Unit (CAR-ICU) Initiative: Surveying Intensive Care Unit Practices in the Management of CAR T-Cell Associated Toxicities, 2020-04-15

• Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment, 2023-06-06

• Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance, 2018-12-04

• Targeting B cell malignancies through human B cell receptor specific CD4 T cells, 2015-11-04

• Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas, 2015-03-31

• Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with Grey Zone Lymphoma, 2016-07-05

• Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment, 2023-02-14

• Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, 2018-08-06

• The promise of CAR T-cell therapy in aggressive B-cell lymphoma, 2018-08-01

• Prospective Isolation of Clonogenic Mantle Cell Lymphoma Initiating Cells, 2010-08-06

• Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit ‘ALL', 2018-02-13

• Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare, 2019-05-14

• The risk of central nervous system relapses in patients with peripheral T-cell lymphoma, 2018-03-14

• Nonstereotyped Lymphoma B-cell Receptors Recognize Vimentin as a Shared Autoantigen, 2013-03-27

• Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, 2018-12-02

• Targeting Wnt pathway in mantle cell lymphoma-initiating cells, 2015-06-06

• The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma, 2016-12-16

• Cross talk between follicular helper T cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment, 2013-05-17

• Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma, 2017-05-09

• Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula, 2012-07-02

• Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma, 2013-08-02

• Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model, 2021-06-03

• CXCR5+CD8+ T cells are localized in B cell follicles and germinal centers and exhibit regulatory and anti-tumor function, 2015-11-04

• Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment, 2016-02-11

• Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma A Review, 2020-02-01

• 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two National Harbor, MD, USA. 9-13 November 2016, 2016-11-16

• Impact of Conditioning Chemotherapy on Lymphocyte Kinetics and Outcomes in LBCL Patients Treated with CAR T-cell Therapy, 2022-09-20

• B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade, 2022-05-26

• ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies, 2016-02-16

• Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis, 2018-06-22

• Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol, 2018-02-13

• Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy, 2021-03-25

• A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy, 2022-10-24

• Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?, 2020-02-07

• Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma, 2020-02-29

• Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer, 2021-02-19

• Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: An open label single arm phase II trial, 2014-09-28

• Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas, 2020-10-05

• Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial, 2022-03-21

• PD-L1+macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphoma, 2023-03-20

• Targetable genetic alterations ofTCF4(E2-2) drive immunoglobulin expression in diffuse large B-cell lymphoma, 2019-06-19

• Chimeric antigen receptor T-cell therapy - assessment and management of toxicities, 2017-09-19

• The impact of cell-of-origin, MYC/Bcl-2 Dual Expression andMYCRearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy, 2021-01-22

• Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma, 2022-08-29

• Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the anti-tumor efficacy of dendritic cells, 2016-09-27

• A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma, 2021-08-26

• Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma., 2020-01-08

• Induction of p53-mediated transcription and apoptosis by Exportin-1 (XPO1) inhibition in mantle cell lymphoma, 2014-06-03

• 3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironmentin vitro, 2017-01-31

• Combination of Pim kinase inhibitor, SGI-1776, with bendamustine in B-cell lymphoma, 2013-10-31

• Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignanciesin vivo, 2017-11-27

• Ibrutinib-Based Therapy for the Treatment of Marginal Zone Lymphoma with Central Nervous System Involvement, 2020-07-10

• Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications, 2021-01-21

• Phase 1 safety and dose escalation of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K in relapsed or refractory lymphoma and multiple myeloma, 2016-03-31

• Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells, 2022-04-28